CVR number 32063071
Industry 86.2200 Specialist medical practice activities

NACMAM ApS

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  0.7% 0.7% 0.7% 0.7% 0.7%  
Bankruptcy risk  3.1% 5.0% 5.0% 4.6% 4.9%  
Credit score (0-100)  58 44 42 45 43  
Credit rating  BBB BBB BBB BBB BBB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales  0 0 0 0 0  
Gross profit  131 111 120 145 129  
EBITDA  131 111 120 145 129  
EBIT  89.5 70.1 79.5 104 88.8  
Pre-tax profit (PTP)  197.3 70.1 79.5 104.0 88.8  
Net earnings  153.9 54.6 62.0 81.1 69.3  
Pre-tax profit without non-rec. items  197 70.1 79.5 104 88.8  
 
See the entire income statement

Balance sheet (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Tangible assets total  1,669 1,628 1,588 1,547 1,506  
Shareholders equity total  2,654 2,598 2,580 2,661 2,730  
Interest-bearing liabilities  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  2,741 2,688 2,680 2,775 2,849  
Net Debt  -258 -240 -184 -25.3 -39.8  
 
See the entire balance sheet

Volume 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  131 111 120 145 129  
Gross profit growth  1.6% -15.3% 8.6% 20.4% -10.5%  
Employees  1 1 1 1 1  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  2,741 2,688 2,680 2,775 2,849  
Balance sheet change%  2.2% -1.9% -0.3% 3.5% 2.7%  
Added value  130.8 110.8 120.2 144.7 129.5  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  -83 -81 -81 -81 -81  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  3.0 4.0 5.0 5.0 5.0  

Profitability 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  68.4% 63.3% 66.1% 71.9% 68.6%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  7.3% 2.6% 3.0% 3.8% 3.2%  
ROI %  7.3% 2.6% 3.0% 3.8% 3.2%  
ROE %  5.8% 2.1% 2.4% 3.1% 2.6%  

Solidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  96.8% 96.6% 96.2% 95.9% 95.8%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -197.1% -216.4% -152.7% -17.5% -30.7%  
Gearing %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.0% 0.0% 0.0%  

Liquidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  15.7 65.5 59.8 51.9 66.1  
Current Ratio  15.7 65.5 59.8 51.9 66.1  
Cash and cash equivalent  257.8 239.7 183.6 25.3 39.8  

Capital use efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  303.0 1,043.6 1,074.3 1,204.1 1,322.1  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  131 111 120 145 129  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  131 111 120 145 129  
EBIT / employee  89 70 80 104 89  
Net earnings / employee  154 55 62 81 69